Deisseroth, A, Zhang W, Cha Y, Yuan T, Chen H, Sims S, Wedrychowski A, Gao P, Huston L, Filaccio M, Claxton D, Kornblau S, Johnson E, Howard O, Andersson B, Giglio A, Gressot L, Kantarjian H, Talpaz M, Khouri I, Champlin R, Andreeff M , Gaozza E, Seong D, Suh S, Ellerson D, Hu G, Chou M
Hands: Among the slowest responses
Individuals with any of the following conditions should consult with their healthcare provider before use and may not be eligible for treatment: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) Known hypersensitivity to GLP-1 or GLP-1/GIP medications or any formulation components, including additives such as vitamin B12 or cobalt Pregnancy or plans to become pregnant (therapy should be discontinued at least two months prior to planned pregnancy) Diabetic ketoacidosis (DKA) or type 1 diabetes Severe gastrointestinal disease (including gastroparesis or active inflammatory bowel disease) Severe cardiovascular disease (including unstable coronary artery disease or heart failure) Recent bariatric or gastrointestinal surgery within the past six months Active cancer currently undergoing chemotherapy or radiation treatment This list is not comprehensive

The approval was based on the OASIS 4 Phase 3 trial , a 64-week study involving 307 adults with obesity or overweight
Some 503A pharmacies continue to dispense patient-specific preparations of BPC-157 pursuant to a valid prescription, on the basis that 503A and 503B operate under separate statutory frameworks (FDCA 503A vs 503B)
Normal insulin function is closely related to mitochondrial function and dynamic balance, and insulin resistance directly leads to mitochondrial dysfunction